Dealmaking Styles of Regional Players
Executive SummaryAs dealmakers, Japanese and mid-sized European drug companies both tend to favor regional, rather than worldwide, agreements. But Europeans tend to pay more upfront, a reflection of the fact that they often prefer to use equity rather than simply cash in making their payments.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.